Where Will Moderna Be in 10 Years? @Themotleyfool #Stocks $MRNA

Where Will Moderna Be in 10 Years? @themotleyfool #stocks $MRNA

Top 5 Infectious Disease News Stories Week of June 28-July 5

This week, Moderna’s mRNA-1010 flu vaccine showed strong phase 3 results, new research reveals that FMT may fail due to functional mismatches between donor microbes and the recipient’s gut, and more.

Moderna Says mRNA Flu Vaccine Sailed Through Trial, Beating Standard Shot

Moderna's mRNA-based seasonal flu vaccine proved 27% more effective at preventing influenza infections than standard flu shots in a Phase 3 trial involving nearly 41,000 people aged 50 and above, the firm said this week. The company announced that mRNA-1010 had an overall vaccine efficacy that was 26.6% higher than conventional shots, rising to 27.4% higher in participants aged 65 and older during the six-month study period. The 2024-2025 flu se…